Efficacy and Safety of HSK31679 in Asian Patients With MASLD: A Randomized Controlled Trial
Feng Xue(Ruijin Hospital), Lai Wei(Nanjing University of Finance and Economics), Le Wang, Peili Bu(Shandong University), Kunyan Hao, Ying Chen(North China University of Science and Technology), Lingchun Lv(Zhejiang Chinese Medical University), Yanhang Gao(Jilin University), Wei Yue, Zhaohui Pei, Tingting Wu(China National Pharmaceutical Group Corporation (China)), Qincong Chen, Bihua Xia, Bihui Zhong(Sun Yat-sen University), Fangqiong Li(Zhejiang Chinese Medical University), Yong Huo(Sun Yat-sen University), Chuanwu Zhu(The Fifth People’s Hospital of Suzhou), Jianming Zhang, Wei Ma(Northeastern University), Guangming Li(Shandong Iron and Steel Group (China)), Qingxian Cai, Laijing Du(First Affiliated Hospital of Henan University of Science and Technology), Chen Liang(Shanghai Public Health Clinical Center), Jinjun Chen(Nanfang Hospital), Jixian Gao(Zhengzhou University), Genshan Ma(Zhongda Hospital Southeast University), Xianyou Ji, Jianlong Sheng, Liu Fei(Xi'an Jiaotong University), Lvfeng Yao
Cited by 2
Related Papers
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Deep learning for the design of photonic structures
|Nature Photonics|2020|1.1k
World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI
|Nature Reviews Cardiology|2014|339